Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
4.67 (USD) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.377 | 1.658 | 1.663 | 0.011 | 0.009 | 0.008 |
| Gross Profit
| 0 | -0.377 | -1.658 | -1.663 | -0.011 | -0.009 | -0.008 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 124.517 | 86.14 | 82.274 | 51.1 | 13.704 | 3.92 | 1.693 |
| General & Administrative Expenses
| 17.741 | 18.821 | 24.714 | 20.391 | 7.824 | 0.403 | 0.386 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 17.741 | 18.821 | 24.714 | 20.391 | 7.824 | 0.403 | 0.386 |
| Other Expenses
| 0 | 0 | -0.027 | -0.047 | 0 | 0 | -0.031 |
| Operating Expenses
| 142.258 | 104.961 | 106.988 | 71.491 | 21.528 | 4.323 | 2.079 |
| Operating Income
| -142.258 | -104.961 | -106.988 | -71.491 | -21.528 | -4.323 | -2.079 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 12.784 | 8.306 | 2.201 | 0.395 | -0.593 | 0.007 | -0.118 |
| Income Before Tax
| -129.474 | -96.655 | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -2.201 | -0.21 | 0.642 | -0.156 | -0.09 |
| Net Income
| -129.474 | -96.655 | -102.586 | -70.886 | -22.763 | -4.316 | -2.197 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.2 | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| EPS Diluted
| -2.2 | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| EBITDA
| -129.081 | -104.584 | -103.129 | -69.433 | -21.517 | -4.307 | -2.161 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |